AU2021339851A1 - Method of treating amyloidosis - Google Patents

Method of treating amyloidosis Download PDF

Info

Publication number
AU2021339851A1
AU2021339851A1 AU2021339851A AU2021339851A AU2021339851A1 AU 2021339851 A1 AU2021339851 A1 AU 2021339851A1 AU 2021339851 A AU2021339851 A AU 2021339851A AU 2021339851 A AU2021339851 A AU 2021339851A AU 2021339851 A1 AU2021339851 A1 AU 2021339851A1
Authority
AU
Australia
Prior art keywords
antibody
subject
dose
amyloidosis
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021339851A
Other languages
English (en)
Other versions
AU2021339851A8 (en
Inventor
Michael KAHSAI
Anthony S. Lubiniecki
Jessica G. RAVIWONG
Susan B. Sobolov-Jaynes
Michael Spector
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caelum Biosciences Inc
Original Assignee
Caelum Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caelum Biosciences Inc filed Critical Caelum Biosciences Inc
Publication of AU2021339851A1 publication Critical patent/AU2021339851A1/en
Publication of AU2021339851A8 publication Critical patent/AU2021339851A8/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
AU2021339851A 2020-09-14 2021-09-14 Method of treating amyloidosis Pending AU2021339851A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078258P 2020-09-14 2020-09-14
US63/078,258 2020-09-14
US202063116100P 2020-11-19 2020-11-19
US63/116,100 2020-11-19
US202163176015P 2021-04-16 2021-04-16
US63/176,015 2021-04-16
PCT/US2021/050316 WO2022056484A1 (en) 2020-09-14 2021-09-14 Method of treating amyloidosis

Publications (2)

Publication Number Publication Date
AU2021339851A1 true AU2021339851A1 (en) 2023-04-13
AU2021339851A8 AU2021339851A8 (en) 2023-04-20

Family

ID=80631942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021339851A Pending AU2021339851A1 (en) 2020-09-14 2021-09-14 Method of treating amyloidosis

Country Status (9)

Country Link
US (1) US20230364228A1 (https=)
EP (1) EP4210753A4 (https=)
JP (1) JP2023541191A (https=)
KR (1) KR20230069161A (https=)
AU (1) AU2021339851A1 (https=)
CA (1) CA3192069A1 (https=)
IL (1) IL301047A (https=)
MX (1) MX2023002997A (https=)
WO (1) WO2022056484A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022346750A1 (en) * 2021-09-14 2024-04-11 Caelum Biosciences, Inc. Method of treating multiple myeloma
CN120322242A (zh) * 2022-09-16 2025-07-15 联邦高等教育系统天普大学 Bag3用于治疗心脏淀粉样变性的方法和用途
WO2025194030A1 (en) 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US20090028847A1 (en) * 2007-04-12 2009-01-29 Trustees Of Boston University Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis

Also Published As

Publication number Publication date
US20230364228A1 (en) 2023-11-16
JP2023541191A (ja) 2023-09-28
AU2021339851A8 (en) 2023-04-20
WO2022056484A1 (en) 2022-03-17
CA3192069A1 (en) 2022-03-17
EP4210753A1 (en) 2023-07-19
MX2023002997A (es) 2023-05-11
EP4210753A4 (en) 2025-01-08
KR20230069161A (ko) 2023-05-18
IL301047A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
US20260042861A1 (en) Formulations of anti-cd38 antibodies for subcutaneous administration
US20230364228A1 (en) Method of treating amyloidosis
CN118416216A (zh) 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
CA3110276A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
KR20250109193A (ko) Fcrn 길항제를 사용하여 루푸스 신염을 치료하는 방법
US20240216470A1 (en) Inducible il-2 and pd-1/pd-l1 combination therapy
CN118043072A (zh) 治疗多发性骨髓瘤的方法
US20240392028A1 (en) Method of treating multiple myeloma
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
US20220031840A1 (en) Method of Treatment
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
EA050760B1 (ru) Способ лечения множественной миеломы
CN116782935A (zh) 治疗淀粉样变性的方法
IL295202A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma
IL293615A (en) Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma
JP2026512040A (ja) 投薬レジメン
JP2025515344A (ja) 抗ｐｄ－１抗体と抗ｅｇｆｒ抗体との組み合わせ及び頭頸部扁平上皮がんの治療におけるその使用
HK40109234A (zh) 用於治疗癌症的方法和组合物
TW202421194A (zh) 包含抗ｇｉｔｒ抗體之用於治療癌症的組合療法
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
WO2026008043A9 (zh) 靶向Nectin-4的抗体药物缀合物和免疫检查点抑制剂联合的用途
HK40110052A (zh) 用於治疗癌症的方法和组合物
EP4324476A2 (en) Methods for treating relapsing forms of multiple sclerosis

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 57 , NO 14 , PAGE(S) 2036 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME CAELUM BIOSCIENCES, APPLICATION NO.2021339851, UNDER INID (71) CORRECT THE APPLICANT NAME TO CAELUM BIOSCIENCES, INC.